Mid-Year Report

RYAN MACKINNON VASAPOLI AND BERZOK, LLP for GENENTECH

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Science/Technology SCI

S. 1695 H.R. 2273 Biotechnology, follow-on biologics

LobbyistCovered position, as disclosed
MATTHEW BERZOK N/A
RODNEY HOPPE N/A
JEFF MACKINNON N/A
DOUGLAS R NAPPI CHIEF COUNSEL, SENATE BANKING COMMITTEE
GEORGE C O'CONNOR COUNSEL, SENATOR LARRY CRAIG
WILLIAM D PHILLIPS N/A
MARK PLANNING N/A
THOMAS RYAN N/A
JOSEPH V VASAPOLI N/A

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 1695 (110th), H.R. 2273 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.